Biosimilars Conference 2011

With billions of dollars worth of biologic drugs going off patient in the next decade, this industry in set to expand at an intensive rate, and the importance of being fully informed of how you and your business will be affected is paramount. By the same token, the rewards of playing an important role in the development of biosimilars, or “Follow On Biologics”, are potentially substantial.

At this conference you can expect to learn about a comprehensive range of pivotal issues in this area, not just relating to the development of the US regulatory pathway and the early steps of the EMA, but also the scientific developmental agenda of major players in the fledgling industry, the unique and exiting position of mAbs in this new arena, how Biobetters and Biosuperiors could challenge second generation biologics, and analysis of global biosimilars pricings structure.